# The role of PCI (Peritoneal cancer index) score in Ovarian Malignancy imaging



R Conroy<sup>1</sup>, L Cunliffe<sup>1</sup>, R Wiles<sup>2</sup>. <sup>1</sup>North West School of Radiology; <sup>2</sup>Liverpool University Hospitals NHS Trust

Ovarian cancer is the 6<sup>th</sup> most common cancer in women in the UK, with 80% presenting with peritoneal metastatic disease<sup>1</sup>. A Multidisciplinary team (MDT) discussion is essential to determine whether primary oncological treatment or surgery is the most appropriate initial management.

Peritoneal cancer index (PCI) is a quantitative scoring system which can be included in radiological reports to aid MDT discussions<sup>2</sup>.

Recent European guidelines suggest a PCI score may be useful in MDT discussions, although currently it is not considered essential<sup>2</sup>.

In our center it is common practice to record the PCI at diagnosis and then again at stage of consideration for cytoreductive surgery (CRS) post chemotherapy.



Figure 1: Region 1 Lesion size score 3, Region 3 Lesion size score 3




Figure 2: Region 0 Lesion size score 3, Region 8 Lesion size score 2

### Results: 84 patients with ovarian cancer were discussed at MDT. 51/84 (59%) had peritoneal disease and a documented PCI at presentation (PCI score range 6-33) patients had patients had patients had best primary primary upportive care surgery chemotherapy Average PCI: 21 (Range 10-33) Average PCI: 17.6 (Range 10-26) 14 patients then went on to have CRS Average PCI at re-discussion: 12.5 (Range 5-17)

- To review the number of patients with ovarian cancer discussed at our tertiary MDT, who had a PCI documented at presentation.
- To review the MDT outcomes for patients with peritoneal disease.

## PCI Score:

To derive a PCI score, the abdomen and pelvis is divided into 13 regions. Each region is score from 0-3 according to the size of disease in that region. The scores from each region are added together to give a total PCI (maximum score is 39.)



6 – Pelvis Region: **0-** Central 7 – Right Lower **1-** Right Upper 8 – Right Flank **2 -** Epigastrium **9 –** Upper Jejunum **3 -** Left Upper **10 –** Lower Jejunum

4 - Left Flank **11 –** Upper Ileum **5** - Left Lower **12 –** Lower Ileum

Lesion Size Score:

LS 0 - No tumour seen

LS 1 - Tumour up to 0.5cm

**LS 2 -** Tumour up to 5.0 cm **LS 3-** Tumour >5.0 cm of confluence

Figure 5: PCI scoring system <sup>4</sup>




Figure 6: Region 12 Lesion size score 2

We conducted a retrospective study of adult patients with ovarian cancer, discussed in our tertiary centre MDT meetings between January- April 2024.

Information was gathered from MDT documentation and the clinical radiology information system (CRIS). For those patients with peritoneal disease, we recorded the PCI at diagnosis (initial presentation) and reviewed the MDT outcome to assess how many patients had primary surgery or primary chemotherapy. We then calculated an average PCI score for each MDT outcome group (e.g. primary surgery and primary chemotherapy).

For a small cohort of patients the PCI was recalculated at time of consideration for cytoreductive surgery, this PCI was again documented.




Figure 3: Region 10 Lesion size score 2




Figure 4: Region 6 Lesion size score 3

### Discussion:

PCI scoring is a useful tool to quantify peritoneal disease.

We regularly use the PCI score(s) in our tertiary centre MDT discussion to aid in clinical decision-making regarding suitability for surgical management and to assess treatment response. We found that patients with a higher PCI at presentation were more likely to be offered primary chemotherapy. Patients whose PCI had decreased after chemotherapy were more likely to then be offered CRS.

It is the joint recommendation from a cohort of European imaging bodies that MDT discussions should include a measure of extent of peritoneal metastases using a quantitative scoring method<sup>3</sup>. Our data suggests use of PCI may be a useful tool to aid MDT discussions at other centres.

Overall, integration of PCI into MDT discussion has become integral in our tertiary center and is valued both by surgical colleagues and the wider MDT. PCI is not a definitive tool, as surgical management depends not only on the volume of disease, but also the site and distribution.

- Cancer Research UK. Ovarian Cancer Statistics. [Online] Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed 04/25
- Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston, MA: Springer; 1996.
- Vandecaveye V, Rousset P, Nougaret S, et al. Imaging of peritoneal metastases of ovarian and colorectal cancer: joint recommendations of ESGAR, ESUR, PSOGI, and EANM. European Radiology. 35, 2712–2722 (2025). https://doi.org/10.1007/s00330-
- Determining the peritoneal cancer index HIPEC.com [Online]